Company Overview of The Translational Genomics Research Institute
The Translational Genomics Research Institute develops earlier diagnostics and treatments. It develops diagnostics, prognostics, and therapies for cancer, neurological disorders, diabetes, and other complex diseases. The company also provides bio4d to offer tools for managing various aspects of the biospecimen lifecycle, including related data enabling clinical genomics data warehouse capabilities for data mining and integrative analysis for the discovery or validation of biomarkers, diagnostics, and therapeutics. In addition, The Translational Genomics Research Institute offers genome technology and core services; genome technology for performing contemporary genetic analysis to benefit the...
445 North Fifth Street
Phoenix, AZ 85004
Founded in 2002
Key Executives for The Translational Genomics Research Institute
Chief Operating Officer and President of TGen Accelerators
President of TGen Foundation
Compensation as of Fiscal Year 2013.
The Translational Genomics Research Institute Key Developments
The Translational Genomics Research Institute and Easton-Bell Sports, Inc Announce Partnership for Biomarker Study of Concussive Injuries
May 14 13
The Translational Genomics Research Institute (TGen), and Easton-Bell Sports, Inc. through its Riddell brand, announced they would work together on a study designed to advance athlete concussion detection and treatment. Information gathered through the study will also be used to develop new football headgear and further refine updates to player monitoring technology. The genesis of this potentially study is to merge a player's genetic information with real-time microelectronic information captured by Riddell's Sideline Response System (SRS). A highly sophisticated, data-intensive system, Riddell SRS provides researchers, athletic staff and players with a wide range of valuable information on the number and severity of head impacts a player receives during games and practices. Employed since 2003 by several well-respected research institutions, Riddell SRS has captured 1.8 million impacts from youth to elite football competition, and its data has led to impactful changes to rules, how the game is played and coached, and has informed new helmet designs. While the joint study will begin with football, the Riddell-TGen partnership has the potential to improve sports equipment manufactured by brands in the broader Easton-Bell Sports portfolio, including headgear for hockey, baseball, cycling, snowsports, and powersports. As part of the study, TGen will work with the Barrow Neurological Institute whose B.R.A.I.N.S. (Barrow Resource for Acquired Injury to the Nervous System) program treats patients who have sustained a traumatic brain or spinal cord injury.
Scottsdale Healthcare Corp. and The Translational Genomics Research Institute Demonstrate Study of New Drug Regimen for Patients with Pancreatic Cancer
Nov 16 12
A new cancer drug combination demonstrated significant improvement in overall survival of late-stage pancreatic cancer patients compared to those receiving standard treatment, according to results of a Phase III clinical trial led by physicians from Scottsdale Healthcare Corp.'s Virginia G. Cancer Center Clinical Trials, a partnership with The Translational Genomics Research Institute. Physicians at the Virginia G. Piper Cancer Center at Scottsdale Healthcare were first to design a clinical trial to determine the safety, tolerability and effectiveness of nab-paclitaxel (Abraxane) in combination with the standard drug gemcitabine in patients with advanced pancreatic cancer. Full results are expected to be presented at the American Society of Clinical Oncology (ASCO) 2013 Gastrointestinal Cancers Symposium in Jan. 24-26 in San Francisco. The pancreas is a gland behind the stomach that secretes enzymes into the upper part of the small intestine to help digestion. It also produces hormones, including insulin, which helps regulate the metabolism of sugars. Advanced pancreatic cancer is fourth most common cause of cancer death in the United States and throughout the world. It is a difficult to diagnose and treat cancer with the lowest survival rates among all cancer types.
The Translational Genomics Research Institute Presents at Interop Las Vegas 2012, May-08-2012 01:00 PM
May 3 12
The Translational Genomics Research Institute Presents at Interop Las Vegas 2012, May-08-2012 01:00 PM. Venue: Mandalay Bay Convention Center, Las Vegas, Nevada, United States. Speakers: Spyro Mousses, Unit Head of Cancer Drug Development Lab - Pharmaceutical Genomics Division and Director of Pharmaceutical Genomics Division.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|